Molecular Pathology

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sykes, T C F
Right arrow Articles by Mosquera, D
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sykes, T C F
Right arrow Articles by Mosquera, D
J Clin Pathol: Mol Pathol 2000; 53:300-306
© 2000 Journal of Clinical Pathology


Review

Thrombophilia, polymorphisms, and vascular disease

T C F Sykes1, C Fegan2 and D Mosquera1

1 Academic Vascular Unit, Birmingham Heartlands Hospital, Bordesley Green East, Birmingham B9 5SS, UK
2 Department of Haematology, Birmingham Heartlands Hospital

Correspondence: Dr Sykes

Thrombophilia traditionally refers to rare inherited defects leading to enhanced coagulation, especially of the venous system. In recent years, a broader search for genetic polymorphisms of prothrombotic genes has been carried out to determine the relative impact on venous and arterial thrombosis. The bulk of evidence is drawn from numerous, often small, heterogeneous, case control association studies, with a variety of end points (deep venous thrombosis, myocardial infarction, or stroke). The data are often conflicting and inconclusive with only factor V Leiden and prothrombin polymorphisms having clear associations with venous thrombosis. Many of the polymorphisms interact with established cardiovascular risk factors, in particular smoking, to increase greatly the risk of a thrombotic episode. Future studies will need to consider the confounding factors of sample size, race, and clinical end points as well gene–environment interactions.

Key Words: thrombophilia • polymorphism • thrombosis • vascular disease







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Molecular Pathology Journal of Clinical Pathology
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2000 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.